Way to Go/No-Go!

Affiliations

¹ Louise McMichael Miracle Professor in Oncology, Associate Chief, Section on Hematology and Oncology, Wake Forest NCORP Research Base, Co-Leader, Neuro-Oncology Program, Wake Forest Baptist Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, North Carolina.

Editorial

Glenn J Lesser. Neuro Oncol. 2020.

. 2020 May 15;22(5):596-597.

doi: 10.1093/neuonc/noaa061.

¹ Louise McMichael Miracle Professor in Oncology, Associate Chief, Section on Hematology and Oncology, Wake Forest NCORP Research Base, Co-Leader, Neuro-Oncology Program, Wake Forest Baptist Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, North Carolina.

No abstract available

Comment on

Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study.
Brenner AJ, Peters KB, Vredenburgh J, Bokstein F, Blumenthal DT, Yust-Katz S, Peretz I, Oberman B, Freedman LS, Ellingson BM, Cloughesy TF, Sher N, Cohen YC, Lowenton-Spier N, Rachmilewitz Minei T, Yakov N, Mendel I, Breitbart E, Wen PY. Brenner AJ, et al. Neuro Oncol. 2020 May 15;22(5):694-704. doi: 10.1093/neuonc/noz231. Neuro Oncol. 2020. PMID: 31844886 Free PMC article. Clinical Trial.
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).
Cloughesy TF, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL, Ellingson BM, Freedman LS, Cohen YC, Lowenton-Spier N, Rachmilewitz Minei T, Fain Shmueli S; GLOBE Study Investigators; Wen PY. Cloughesy TF, et al. Neuro Oncol. 2020 May 15;22(5):705-717. doi: 10.1093/neuonc/noz232. Neuro Oncol. 2020. PMID: 31844890 Free PMC article. Clinical Trial.

1. Cloughesy TF, Brenner A, de Groot JF, et al. . A randomized controlled phase III study of VB-111 combined with bevacizumab vs. bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). Neuro Oncol. 2020;22(5):705–717. - PMC - PubMed
1. Brenner AJ, Peters KB, Vredenburgh J, et al. . Safety and efficacy of VB-111, an anti-cancer gene-therapy, in patients with recurrent glioblastoma: results of a phase I/II study. Neuro Oncol. 2020;22(5):694–704. - PMC - PubMed
1. Grossman SA, Ye X, Lesser G, et al. ; NABTT CNS Consortium Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011;17(16):5473–5480. - PMC - PubMed
1. Lowenstein PR, Castro MG. Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail? Curr Gene Ther. 2009;9(5):368–374. - PMC - PubMed
1. Tobias A, Ahmed A, Moon KS, Lesniak MS. The art of gene therapy for glioma: a review of the challenging road to the bedside. J Neurol Neurosurg Psychiatry. 2013;84(2):213–222. - PMC - PubMed